Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Sana Biotechnology, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
99.6
133
249
286
262
216
132
General and administrative
21.8
28.3
50.4
71.6
73.3
64
44.3
Operating expenses
141
286
357
273
293
273
250
Operating income
-141
-286
-357
-273
-293
-273
-250
Other non-operating income
-0.03
0.1
0.31
-0.67
-0.05
-4.51
2.31
Pre-tax income
-138
-285
-356
Income tax
-7.55
0
Net income
-131
-285
-356
-269
-283
-267
-244
EBITDA
-139
-280
-346
-257
-276
-257
-238
EPS, basic
-26.68
-21.92
-2.14
-1.43
-1.46
-1.16
-0.96
EPS, diluted
-26.68
-21.92
-2.14
-1.43
-1.46
-1.16
-0.96
Shares, basic (weighted)
4.9
13
166
188
195
231
253
Shares, diluted (weighted)
4.9
13
166
188
195
231
253
Balance sheet
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
81.8
125
253
177
134
128
71.9
Short-term investments
253
298
247
71.7
24.9
66.5
Other current assets
6.2
7.11
14.4
4.49
4.48
6.1
Total current assets
384
558
444
214
161
149
Property, plant and equipment
46.8
65.5
66.9
70.7
77.3
26.9
Lease right-of-use assets
63.2
96.3
92.5
74.9
58
38.3
Goodwill
141
141
141
141
141
141
Intangible assets
59.2
59.2
59.2
59.2
59.2
59.2
Long-term investments
33.7
196
10.1
Other non-current assets
0.19
5
4.6
6.37
5.12
3.17
Total assets
730
1,129
823
565
501
417
Accounts payable
2.25
2.22
2.86
4.11
5.21
1.67
Accrued liabilities
16
21.1
26.4
23.7
14.4
13.2
Total current liabilities
31.5
99.2
112
64.5
45.4
78.7
Lease liabilities
68.2
102
95.9
90.9
81.7
63.9
Other non-current liabilities
0.54
9.9
10.6
Total liabilities
299
401
323
278
251
256
Paid-in capital
8.22
1,515
1,558
1,626
1,855
2,010
Retained earnings
-429
-785
-1,055
-1,338
-1,605
-1,849
Other comprehensive income
0.03
-1.37
-4.33
-0.06
0.01
0.03
Shareholders' equity
-143
-421
729
499
288
251
161
Total equity
-143
-421
729
499
288
251
161
Total liabilities and equity
730
1,129
823
565
501
417
Shares outstanding
16.2
185
191
198
224
267
Cash flow statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-131
-285
-356
-269
-283
-267
-244
Depreciation and amortization
1.83
5.92
11.1
15.6
17.5
15.5
12.8
Stock-based compensation
1.5
5.83
22.4
38.3
35.5
37.7
25.5
Deferred income tax
-7.55
Change in payables
-0.42
1.98
-0.27
1.06
1.03
1.38
-3.55
Cash from operations
-85.5
-138
-251
-290
-254
-223
-144
Capital expenditures
-26.1
-23.9
-29.9
-20.9
-20
-33.4
-0.94
Acquisitions
-3.2
Purchases of investments
-142
-387
-491
-78.7
-158
-226
-87.3
Sales and maturities of investments
83
159
280
310
350
277
46.6
Cash from investing
-87.9
-253
-246
211
172
17.5
-40.2
Stock issued
5.35
4.31
27
181
126
Cash from financing
224
436
632
4.91
31.6
200
129
Net change in cash
50.4
45.1
135
-74.6
-49.9
-5.95
-55.3
Free cash flow
-112
-162
-281
-311
-274
-257
-145
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $2.95 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-137.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-49.1%
Net income / average total assets.
Return on invested capital (ROIC)
-177.3%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-35.8%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-31.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-16.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-20.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-10.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
9.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
10.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
81.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.38x
Current assets / current liabilities.
Quick ratio
1.30x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.30x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$0.46
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.45
Cash from operations / diluted weighted shares.
Book value per share
$0.52
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
5.70x
Market cap / shareholders' equity. Only when equity is positive.
FCF yield
-15.3%
Free cash flow / market cap.
Earnings yield
-24.0%
Net income / market cap (the inverse of P/E).
Was Sana Biotechnology, Inc. profitable in fiscal 2025?
No. It reported a net loss of $244.2M.
How much free cash flow did Sana Biotechnology, Inc. generate in fiscal 2025?
Cash from operations of $143.8M minus capital expenditures of $938.0K left free cash flow of -$144.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.